We previously identified high levels of Na v 1.7 voltage-gated sodium channel a-subunit (VGSCa) mRNA and protein in human prostate cancer cells and tissues. Here, we investigated auxillary b-subunit (VGSCbs) expression. In vitro, the combined expression of all four VGSCbs was significantly (B4.5-fold) higher in strongly compared to weakly metastatic cells. This was mainly due to increased b1-expression, which was under androgenic control. In vivo, b1-b4 mRNAs were detectable and their expression in CaP vs non-CaP tissues generally reflected the in vitro levels in relation to metastatic potential. The possible role(s) of VGSCbs (VGSCa-associated and VGSCaindependent) in prostate cancer are discussed.
Introduction
Functional expression of voltage-gated sodium channels (VGSCs), determined by patch-clamp electrophysiological recording, was found to distinguish strongly and weakly metastatic human/rat prostate cancer (CaP) cells: PC-3/MAT-LyLu and LNCaP/AT-2, respectively.
1,2 Importantly, blocking VGSC activity in CaP cells with the highly specific VGSC-blocker tetrodotoxin suppressed in vitro cellular behaviours integral to metastasis, especially directional motility and Matrigel invasion. [1] [2] [3] [4] Thus, VGSCs could actively contribute to the metastatic process. The VGSC a-subunit (VGSCa) expressed at the highest levels and most likely to be responsible for ion pore formation was Na v 1.7.
5 mRNA levels of this VGSCa were also markedly upregulated in CaP in vivo, increasing with Gleason grade. 6 In fact, receiver operator curve analysis suggested that Na v 1.7 could be an effective in vivo marker for CaP. 6 VGSCas are often, but not always, physically associated with one or more smaller, transmembrane auxillary b-subunit proteins (VGSCbs). Four different VGSCb genes have been identified in the genomes of higher vertebrates. [7] [8] [9] [10] At least one of these (b1) can be expressed in different isoforms, generated by alternative splicing and intron-retention mechanisms. [11] [12] [13] VGSCbs can affect VGSC functioning via multiple mechanisms, including modification of voltage-dependent gating, activation and inactivation. 7, [14] [15] [16] [17] These subunits can also increase the amplitude of VGSC currents by (i) modulating the intracellular trafficking of VGSCa protein (thereby incorporating more VGSCs into the cell's plasma membrane) and (ii) increasing their cell surface stability via association with cytoskeletal molecules such as ankyrin. 7, 8, 18, 19 VGSCbs are unique among voltage-gated ion channel auxillary subunits in that they can also function independently of pore-forming VGSCas, in cell adhesion, cell migration and in neurite outgrowth. [20] [21] [22] [23] Indeed, it has been proposed that the VGSCa-independent functions of VGSCbs may be more important than their role in modulating VGSC activity. 19 VGSCbs participate in both homophilic cell-cell interaction (for example, resulting in ankyrin recruitment at contact points 22 ), and heterophilic adhesion with contactin and neurofascin, 23, 24 but can also associate with extracellular matrix molecules (for example, tenascin-C and tenascin-R) to induce cellular repulsion. 20, 25 VGSCb-expression has not previously been investigated in CaP cells or tissues despite (i) adhesion/ migration being of fundamental importance to metastasis 26 and (ii) co-transfection studies indicating that Na v 1.7 can associate with VGSCbs. 27, 28 Here, we used real-time reverse transcriptase (RT)-PCR techniques to investigate expression of VGSCb1-b4 mRNAs since antibodies to all four VGSCbs were not commercially available. Thus, VGSCb mRNA-expression in human prostatic cell lines of a range of metastatic potentials was determined and compared with expression in vivo, using biopsy samples taken from CaP patients and agematched non-CaP controls (in a quantitative approach similar to that which we used before to identify Na v 1.7 as a potential marker for CaP 6 ). The main aims were to determine (i) which VGSCb(s) were expressed and (ii) whether VGSCb mRNA-expression levels were altered in the disease state.
Materials and methods

Tissue culture
Three human CaP cell lines of increasing metastatic potential were used: LNCaP, PC-3 and PC-3M, maintained in RPMI-1640 growth medium containing 4 mM L-glutamine, 1.5 g l À1 sodium bicarbonate, 1 mM Na pyruvate, 4.5 g l À1 glucose and 10 mM HEPES. A fourth cell line, PNT2-C2, 29 derived from 'normal' prostatic epithelial cells immortalized with SV40 was grown in RPMI-1640 medium containing only 4 mM L-glutamine. For all four cell lines, growth medium was supplemented with 10% fetal bovine serum and cultures were maintained in a 37 1C incubator with 5% CO 2 . Cells were plated in 10 cm dishes at six serial densities (ranging from 3.2 Â 10 5 to 2.0 Â 10 7 cells per dish) and harvested after 2 days.
Androgen treatment
PC-3 or LNCaP cells (6.25 Â 10 5 ) were plated in normal growth medium in 10 cm dishes. After 2 days, the medium was removed, cells washed twice with phosphate-buffered saline and then re-fed with normal growth medium supplemented with 10% charcoalstripped fetal bovine serum containing either (i) 10 nM (5a, 17b)-17-hydroxy-androstan-3-one (dihydrotestosterone (DHT), the predominant androgen found in human prostate) in 0.01% ethanol; (ii) 100 nM DHT in 0.01% ethanol or (iii) 0.01% ethanol only. RNA was extracted from the cells after 1, 2 and 3 days of treatment.
Prostate biopsy samples
Twenty prostate tissue samples, consisting of five benign prostatic hyperplasia with no evident CaP (following thorough histopathological examination) and 15 CaP, were obtained from patients undergoing needle-biopsies or radical prostatectomy for biopsy-proven adenocarcinoma at St Mary's Hospital, London, with local ethics approval. The patients varied in age from 47 to 83 years. Those with diagnosed CaP had summed Gleason gradings ranging from 4 to 8. All specimens were snapfrozen in liquid nitrogen in the operating room and stored at À80 1C until used for RNA extraction.
RNA extraction and cDNA synthesis
For cell lines, RNA was extracted using Trizol (Invitrogen, Paisley, UK), according to the manufacturer's instructions, and then subjected to DNase I treatment (Amersham Pharmacia Biotech, Little Chalfont, UK). For tissues, RNA was extracted using the StrataPrep Total RNA Miniprep kit (Stratagene, Cambridge, UK), as described previously. 6 Approximate RNA quality was verified visually by gel electrophoresis and spectrophotometrically from 260/280 nm absorbance ratios. One microgram of total RNA, as determined by spectrophotometric measurement at 260 nm, was then used as the substrate for single-stranded cDNA synthesis using Superscript II reverse-transcriptase (Invitrogen). Reactions were primed with 250 ng random hexamer mix and performed in a 20 ml final volume. For real-time PCR experiments, this was subsequently made up to 100 ml with H 2 O, once the reverse-transcription process was completed.
Fixed endpoint PCR and VGSCb cloning
Specific PCRs were performed on each of two extracts of the cell lines utilizing the primer pairs listed in Table 1 . These PCRs amplified nucleotides corresponding to 58, 48, 54 and 67% respectively, of the coding regions of the VGSCbs. Amplified products spanned at least one conserved intron position. Reactions were performed on 2.5 ml of the synthesized cDNA, using 200 mM of each dNTP (Amersham Pharmacia Biotech), 1 unit of Taq DNA polymerase (Amersham Pharmacia Biotech), 1 Â Taq buffer and 0.5 mM of each primer, in a final volume of 20 ml, as follows: 94 1C for 5 min; 1 U enzyme added; 94 1C for 1 min; 60-64 1C for 1 min; 72 1C for 1 min, with the main section repeated 35-45 times (depending on the reaction). In each PCR run, a blank reaction without added cDNA was also performed to control for crosscontamination from other sources. All products were analysed by gel electrophoresis on 0.8% agarose gels and those derived from LNCaP and PC-3 cells were gel purified, ligated into the pGEM T-vector (Promega pGEM T-vector System) and used to transform E. coli (pMosBlue, Amersham Pharmacia Biotech). Plasmid DNA was recovered from bacterial cell cultures following blue/white, X-gal/b-galactosidase selection using a modified version of the Vistra Labstation 625 miniprep procedure (Vistra DNA Systems, Amersham Pharmacia Biotech) and resultant clones were sequenced using Amersham Thermo Sequenase fluorescent cycle sequencing kits and the Vistra DNA 725 automated sequencer, as described previously. 5 
Real-time PCRs
Real-time PCR utilizing SYBR I Green technology was performed using the DNA Engine Opticon system (MJ Research, Waltham, MA, USA) to determine VGSCb-expression levels in the four cell lines. VGSCb primer pairs used were as described above. Three 'control' genes known to be expressed at similar levels in all four cell lines (b-actin, b2-microglobulin and NADH-cytochrome b5 reductase) 5, 6, 30 were amplified from all cDNAs and used as 'RNA load' normalizing genes, controlling for possible variables including sample-to-sample differences in RNA input, RNA quality and reverse-transcription efficiency that could contribute to inter-sample expression differences. Reactions were performed simultaneously on each sample in triplicate, in a final volume of 20 ml, containing 5 ml cDNA, 500 nM of each specific primer and 1 Â QuantiTect SYBR Green PCR mix (Qiagen, Crawley, UK). Amplification was via Table 1 . Experiments with prostate tissues were performed as above except that b-actin, b2-microglobulin and cytokeratin-8 31 were utilized as normalizing genes.
Data analysis
For real-time PCRs, the threshold amplification cycle (C t ) representing the first discernable amplification cycle above which, the product fluorescence was above the background noise was determined for each reaction using the Opticon software. Subsequently, these values were analysed using the 2 ÀDDCt method 6,32 to determine target-expression levels (expressed as means7s.d.). This analysis method was valid since all VGSCb subtype PCRs worked with similar efficiencies, as determined by reactions performed on serial dilutions of cDNA derived from LNCaP, human umbilical vein endothelial cells and RH-1 neuroblastoma cells (data not shown). The VGSCbexpression in each sample was normalized relative to the sample-matched expression level of all three normalizing genes. Differences in VGSCb-expression levels between strongly and weakly metastatic cell lines were tested for statistical significance using analysis of variance followed by Bonferroni post hoc tests and P-values o0.05 were considered significant. In vitro and in vivo mRNAexpression differences for (a) androgen-treated vs nontreated CaP cells, (b) CaP vs non-CaP samples and (c) low-grade vs high-grade CaPs, were tested for statistical significance by comparing normalized means and medians using the non-parametric Mann-Whitney U-test (a and b) and the Kruskal-Wallis test (c). 33 
Results
Expression of VGSCb subunits in vitro
Fixed endpoint PCRs showed that all four known VGSCbs were expressed in each of the prostate epithelial cell lines studied (Figure 1a ). Two VGSCbs (b3 and b4) were present in more than one splice form, with RT-PCRs amplifying products from an exon-skipped form expressed at lower levels than the full-length transcript (Figure 1a ). These isoforms, if translated, would code for highly truncated VGSCbs lacking the transmembrane domain with presently unknown function, if any. Using PC-3M cells for relative measurements, real-time RT-PCR determined that the total VGSCb level in strongly metastatic cells was on average 4.5-fold higher than in non/weakly metastatic cells: 20.578.6% (combined PNT2-C2 and LNCaP mean) vs 92.4710.8% (combined PC-3 and PC-3M mean) (Po0.05; Figure 1b ). These data were essentially the same using all three normalizing genes (not shown).
The four VGSCb subtypes were expressed at markedly different levels within each cell line (Figure 1c) . b1 was predominant in every case, typically constituting 490% of the total VGSCb mRNA expression. b3 (3-7%) and b4 (o2%) were present at lower levels, and b2-expression was notably very low in all four cell lines studied. Sodium channel b-subunits in prostate cancer JKJ Diss et al
Increased total VGSCb-expression in strongly metastatic cell lines was mainly a result of increased b1-expression (Figure 2a) . On average, b1-expression was 5-fold higher in strongly vs weakly metastatic cells: Figure 2b ). The observed cell line differences in VGSCb levels were maintained at comparable cell densities over an B100-fold range (data not shown). In summary, in CaP cells of strong metastatic potential, expression of b1 was significantly greater and b4 (present at a much lower level) significantly lower, while b2/b3 remained unchanged, compared to cells of weak metastatic potential.
Comparison with VGSCa-expression in vitro
We next analysed VGSCb mRNAs with respect to the expression of the predominant VGSCa in metastatic CaP cells, Na v 1.7. 6 A very similar profile was obtained for PC-3 and PC-3M cells (Figure 2c) . Levels of the predominant b1 were 6-to 8-fold higher than Na v 1.7 in strongly metastatic cells (PC-3 and PC-3M cells, respectively; Po0.05 for both; Figure 2c ). In contrast, b3, the second most abundant VGSCb in these cells, was expressed four-to sixfold lower than Na v 1.7. Thus, assuming similar translation efficiencies, strongly metastatic cells could contain significant amounts of b1 not associated with Na v 1.7. It would follow from the 5-fold difference in b1 mRNA levels between strongly and weakly metastatic cells that even PNT2-C2 and LNCaP cells would possess sufficient b1 to associate with all the Na v 1.7 in PC-3 and PC-3M cells (Figure 2c ).
Effect of androgen treatment on b1 mRNA expression
Since strongly and weakly metastatic cells also differ in their androgen sensitivity, we investigated whether stimulating the androgen receptor (AR) with DHT might reduce VGSCb-expression. Application of 10 or 100 nM DHT to androgen-deprived AR-positive LNCaP cells over a 3-day time period increased mRNA levels of the prostate-specific antigen gene, used here as a positive control, by up to 15-fold in a time-dependent manner (Figure 3a) , as reported previously. 34 Importantly, DHT treatment significantly decreased b1-expression in LNCaP cells (Figure 3b) . A 1.6-fold reduction in b1 levels was apparent following DHT application at 24 and 48 h time points but this effect was lost after 72 h of treatment. Surprisingly, PC-3 cells also responded to DHT treatment with significant (two-to threefold) timedependent increases in b1 and Na v 1.7 mRNA expression (Figure 3b ).
VGSCb mRNA expression in vivo mRNAs of the four VGSCbs were readily detected in all human prostate biopsy tissues tested, as found in vitro. However, (i) the derived C t values for the VGSCb subtypes were similar, indicating that expression levels of b1-b4 were comparable in the CaP/non-CaP biopsy samples, unlike the cell lines, and (ii) the medianexpression levels were not significantly different between non-CaP and CaP tissues (Figures 4a-d) . In contrast, Na v 1.7 and IL-6, known to be expressed at greatly increased levels in CaP vs non-CaP tissues, 6, 35 showed 19-and 42-fold median increases, respectively, in CaP vs non-CaP tissues and these differences were significant (Po0.05 for both; Figures 4e and f) . These data were essentially the same when normalized with respect to all three normalizing genes. VGSCb-expression was also analysed within the CaP samples in relation to Gleason score divided into high (sum X6) and low (sumo6) grades. 4 This analysis also did not reveal a significant difference in VGSCb-expression in high-grade vs low-grade CaP samples. A different approach, plotting in vivo vs in vitro fold-changes in b1-b4 and Na v 1.7 mRNA-expression levels revealed a significant positive linear correlation, close to the origin ( Figure 5 ). This analysis of fold differences suggested that VGSCbexpression was likely to be altered in CaP in vivo in line with the in vitro changes.
Discussion
The main results of the present study are as follows: (1) mRNAs of all four VGSCbs were expressed in human prostate epithelial cell lines, overall at much higher levels in strongly vs weakly metastatic cells. (2) b1 was predominant and its expression level was much higher 
VGSCa/b-expression in CaP
VGSCa mRNA levels were shown previously to be significantly upregulated with increased metastatic potential in CaP with 420-fold higher overall expression in strongly compared to weakly metastatic human CaP cell lines, including an B1000-fold elevation in the expression of a particular VGSCa subtype, Na v 1.7. 5 However, this B1000-fold in vitro elevation translated to a much smaller, but still measurable B20-fold significant increase in Na v 1.7 mRNA in CaP vs non-CaP in vivo. 6 In the present study, we found that VGSCb mRNA levels were much less altered with cellular metastatic potential in vitro. Thus, VGSCb mRNA levels overall were only B4.5-fold higher in strongly metastatic (PC-3 and PC-3M) compared to weakly metastatic (PNT2-C2 and LNCaP) cells, the difference being almost entirely due to the upregulation of b1.
No statistically significant difference was evident in the expression of any of the four VGSCbs between CaP and non-CaP in vivo. This may have been due to the nature of the whole biopsy tissue chunks, with epithelial cells (from which CaP cells arise) only constituting a small fraction of the overall content. In such a situation, any epithelial cell-specific VGSC-expression changes with CaP in vivo would be hard to detect, especially if the non-epithelial cell types present in prostate (for example, smooth muscle cells, peripheral nerves, fibroblasts) also expressed significant levels of VGSCs, which is very likely. [36] [37] [38] [39] Indeed, although not statistically significant, median fold-changes in vivo (non-CaP vs CaP) did appear to correlate very well with corresponding in vitro changes (between strongly and weakly metastatic cells), as shown in Figure 5 . In particular, (a) the direction of the change is the same for b1 (increased with disease progression in vitro and in vivo) and b4 (decreased with disease progression), and (b) the magnitude of the in vivo change for b1 and b4 is consistent with the B50-fold 'dilution' of the in vitro change observed previously for Na v 1.7. Together, these analyses would suggest that our in vitro and in vivo findings show considerable consistency. Further work exclusively on the epithelial/CaP cells of micro-dissected biopsy tissues would clarify the in vivo situation further.
VGSCa and VGSCb interactions in CaP cells
The predominant VGSC a-and b-subunits in CaP cells, Na v 1.7. and b1, are also coexpressed in numerous other cell types, such as Schwann cells. 40 Importantly, when coexpressed in Xenopus oocytes, Na v 1.7 and b1 were found to functionally associate in a 1:1 ratio, with the resultant VGSC currents exhibiting more rapid inactivation, a small but significant (B5 mV) hyperpolarizing shift in steady-state activation and inactivation, and accelerated recovery from fast inactivation, compared to currents resulting from Na v 1.7 a-subunit expression alone. 41, 42 In the present study, we found that Na v 1.7 mRNA levels were much lower than b1, even in strongly metastatic cells (Figure 2c) . Indeed, assuming similar translation efficiencies, there is more than required b1-expression in CaP cells (regardless of metastatic potential) to associate in a 1:1 ratio with Na v 1.7. This may explain why there is no need for a large increase in b1-expression (concomitant with the large increase in VGSCa-expression) in strongly metastatic CaP cells, and would also be consistent with overexpression of VGSCa alone in LNCaP cells being sufficient to increase significantly their in vitro invasiveness. 43 Despite the absence of a large increase in VGSCbexpression, these subunits might still have an important role in VGSC functioning in CaP, and thus in VGSCmediated potentiation of metastatic cell behaviours. Indeed, reducing b1-expression or perturbing its association with Na v 1.7 could alter key channel properties such as activation/inactivation and recovery from fast inactivation that would result in less VGSC activity and inhibition of VGSC-potentiated metastatic cell behaviour. Furthermore, a reduction in VGSCb-expression would also likely cause a reduction in the amount of functional (cell surface) sodium channels via intracellular VGSCa protein trafficking and reduced cell surface stability mechanisms. It is also noteworthy that VGSCb association can significantly alter the efficacy of VGSC-blocking drugs. For example, blockage of Na v 1.3 by lidocaine was reduced in a concentration-dependent manner by coexpression with b1 and to a lesser extent with b3. 44 Thus, reduction of VGSCb-expression, and b1 in particular, could be a successful strategy for reducing VGSC activity (and hence metastatic cell behaviour) via several mechanisms.
VGSCa-independent roles for VGSCbs in CaP cells
If VGSCbs are more abundant than VGSCas in CaP cells, they will either be 'inactive' in a large intracellular pool awaiting VGSCa upregulation, or, perhaps more likely, may be functioning independently of VGSCas. Important VGSCa-independent roles of VGSCbs in cell adhesion and migration, via interactions with extracellular matrix and cell adhesion molecules, have been documented. [19] [20] [21] [22] [23] [24] [25] Such effects are known to also be of fundamental importance to the metastatic process. More recently, a novel role for VGSCbs in p53-dependent apoptosis has been suggested. 45 Two p53-response elements were located in the b3 gene and b3 was found to be markedly upregulated by (a) p53 overexpression and (b) DNA damage in p53-expressing cell lines. Furthermore, overexpression of b3 with p53 in glioma and osteosarcoma cells reduced their colony-forming ability. Since PC-3 and PC-3M cell lines carry mutations of the p53 gene that prevent its normal expression, 46 the functional role of b3 may be different in strongly vs weakly/non-metastatic cells.
Androgen regulation of VGSCbs in CaP cells
Differences in b1 levels in the different CaP cell lines raised the possibility that its expression in these cells is under the control of androgen. Indeed, treatment of androgen-deprived, AR-positive LNCaP cells with DHT revealed an inhibitory influence of androgen on b1-expression, consistent with lower basal levels of b1 mRNA compared with AR-negative cells. Furthermore, and surprisingly, androgen treatment of PC-3 cells increased b1-expression. Since these cells do not possess functional AR this effect must be mediated by a non-AR mechanism. Thus, b1-expression in CaP cells is under androgen control in both AR-positive and negative cells but in opposite directions. Importantly, Na v 1.7-expression was also affected (increased) by androgen in ARnegative cells, consistent with the proposed role of Na v 1.7 in CaP metastasis and the classic role of androgen in CaP progression. 47 The effects of androgen on ARnegative cells may involve cross-talk with growth factor (for example EGF) signalling pathways 47 also known to regulate VGSC expression and activity. 48 
Conclusion
In the present study, we found that auxillary b-subunits of VGSCs are expressed in CaP cells in vitro and in vivo. VGSCb-expression was significantly higher in strongly compared to weakly metastatic cells in vitro, mainly due to increased b1-expression. However, this increase was significantly less than that previously observed for the predominant VGSCa, Na v 1.7. Median VGSCb-expression levels generally reflected in vitro changes, but did not individually reach statistical significance. Even without strikingly altered expression, VGSCbs are likely to have dual importance in CaP. First, VGSCbs, especially b1, can modulate VGSC functioning and, thus, VGSC-mediated potentiation of metastasis. Second, independently of VGSCas, VGSCbs can have an important role(s) in modulating cell adhesion, an integral part of the metastatic cascade. Accordingly, reducing-expression of the predominant VGSCb (b1) or perturbing its association with Na v 1.7 could be a successful strategy for reducing metastatic cell behaviour.
